PTO Rescinds Regs Reviled By Pharma, But Rule-Making Battle Continues

While biotech and pharma companies continue to face myriad patent battles they have one less worry now that the U.S. Patent and Trademark Office has dropped its controversial rules to limit the number of patent claims and continuation filings an applicant may submit